[Bounderies of the authorization to market and the therapeutic impass].
Samama
C M
CM
D000925:Anticoagulants / Q000009:adverse effects* / Q000627:therapeutic use*; D002809:Chondroitin Sulfates / Q000009:adverse effects* / Q000627:therapeutic use*; D003871:Dermatan Sulfate / Q000009:adverse effects* / Q000627:therapeutic use*; D017277:Drug Approval / Q000331:legislation & jurisprudence*; D004338:Drug Combinations; D005602:France; D006493:Heparin / Q000009:adverse effects; D006497:Heparan Sulfate / Q000009:adverse effects* / Q000627:therapeutic use*; D024764:Hirudin Therapy; D006629:Hirudins / Q000009:adverse effects* / Q000031:analogs & derivatives; D006801:Humans; D011994:Recombinant Proteins / Q000009:adverse effects* / Q000627:therapeutic use*
D000925:Anticoagulants; D002809:Chondroitin Sulfates; D003871:Dermatan Sulfate; D004338:Drug Combinations; D006493:Heparin; D006497:Heparan Sulfate; D006629:Hirudins; D011994:Recombinant Proteins; C035838:danaparoid; C083544:lepirudin